The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York GOP lawmakers ask RFK Jr. to make FDA unleash risky peptides like BPC 157 The Niche The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion FDA Compliance for Peptide Therapy and BPC 157 Holt Law